1. AB0552 Relative efficacy and tolerability of intravenous and subcutaneous abatacept compared with tumor necrosis factor inhibitors in rheumatoid arthritis patients with an inadequate response to conventional disease-modifying antirheumatic drugs. (23rd January 2014) Authors: Hochberg, M.; Berry, S.; Broglio, K.; Nadkarni, A.; Rosenblatt, L.; Trivedi, D.; Hebden, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB1353 Comorbidity and cost burden of patients prior to use of second line biologic for rheumatoid arthritis. (23rd January 2014) Authors: Trivedi, D.; Rosenblatt, L.; Darkow, T.; Chastek, B.; Hebden, T. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0301 Outcomes of Patients with Rheumatoid Arthritis and Comorbid Hyperlipidaemia. (23rd January 2014) Authors: Rosenblatt, L.; Curtis, J. R.; Yang, A.; Hebden, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0522 Comparison of Cost- Efficacy of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Patients with Rheumatoid Arthritis. (23rd January 2014) Authors: Khanna, D.; Massarotti, E.; Rosenblatt, L.; Budd, D.; Sabater, J.; Hebden, T. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗